Literature DB >> 6158759

Deficient natural killer cell activity in x-linked lymphoproliferative syndrome.

J L Sullivan, K S Byron, F E Brewster, D T Purtilo.   

Abstract

The activity of natural killer cells was found to be deficient in 10 of 12 males with X-linked lymphoproliferative syndrome, a life-threatening proliferation of lymphocytes after infection by Epstein-Barr virus. The activity levels of natural killer cells from affected males were increased after treatment with interferon in vitro, but normal levels of killing were not obtained. Deficient activity of killer cells in individuals with immunodeficiency and chronic infection by Epstein-Barr virus may contribute to the development of lymphoproliferative disorders.

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6158759     DOI： 10.1126/science.6158759

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


  46 in total

1.  Epstein-Barr virus BARF1 protein is dispensable for B-cell transformation and inhibits alpha interferon secretion from mononuclear cells.

Authors:  J I Cohen; K Lekstrom
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

Review 2.  X-linked lymphoproliferative disease (XLP) as a model of Epstein-Barr virus-induced immunopathology.

Authors:  D T Purtilo
Journal:  Springer Semin Immunopathol       Date:  1991

3.  Immune function in chronic active Epstein-Barr virus infection.

Authors:  R Kibler; D O Lucas; M J Hicks; B T Poulos; J F Jones
Journal:  J Clin Immunol       Date:  1985-01       Impact factor: 8.317

4.  Cloning and chromosomal assignment of a human cDNA encoding a T cell- and natural killer cell-specific trypsin-like serine protease.

Authors:  H K Gershenfeld; R J Hershberger; T B Shows; I L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

5.  Structural basis for the interaction of the free SH2 domain EAT-2 with SLAM receptors in hematopoietic cells.

Authors:  M Morra; J Lu; F Poy; M Martin; J Sayos; S Calpe; C Gullo; D Howie; S Rietdijk; A Thompson; A J Coyle; C Denny; M B Yaffe; P Engel; M J Eck; C Terhorst
Journal:  EMBO J       Date:  2001-11-01       Impact factor: 11.598

Review 6.  X-linked lymphoproliferative disease: genetic lesions and clinical consequences.

Authors:  Andrew J MacGinnitie; Raif Geha
Journal:  Curr Allergy Asthma Rep       Date:  2002-09       Impact factor: 4.806

Review 7.  Tumor cells do not arise frequently.

Authors:  W Den Otter
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

8.  Defective control of Epstein-Barr virus-infected B cell growth in patients with X-linked lymphoproliferative disease.

Authors:  N Yasuda; P K Lai; J Rogers; D T Purtlo
Journal:  Clin Exp Immunol       Date:  1991-01       Impact factor: 4.330

9.  In vitro enhancement of natural killer cell activity against herpesvirus-infected targets in patients with acute lymphocytic leukemia.

Authors:  J R McKolanis; A H Ragab; D S Schmid
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

10.  Epstein-Barr serology in immunodeficiencies: an attempt to correlate with immune abnormalities in Wiskott-Aldrich and Chediak-Higashi syndromes and ataxia telangiectasia.

Authors:  E Vilmer; G M Lenoir; J L Virelizier; C Griscelli
Journal:  Clin Exp Immunol       Date:  1984-02       Impact factor: 4.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.